Veradigm Ambient Scribe

Two independent reasons converge on C. First the platform not algorithm precedent applied across this category to ModMed, Elation Health, Oracle Health and NextGen: the module sits inside the Veradigm EHR and nobody selects Veradigm because of it. Second, and more decisive, the model is not Veradigm's. The product is expressly powered by AvodahMed, which places Veradigm in the position this index graded HeartSciences on, distributing a third party algorithm rather than owning one. Credit where due: Veradigm names its OEM in its own launch materials rather than presenting the intelligence as its own, which is more candour than most white label arrangements offer. The grade describes the mechanism, not the quality of the output.

Sits on the conservative side of the split now running through this category. Diagnosis codes are presented as ICD-10 SUGGESTIONS for provider review rather than pre filled, and no evidence was found of ambient order or prescription drafting of the kind Oracle Health and Sunoh.ai ship. One capability to watch: real time clinical insight prompts tuned to practice protocols surface care considerations during the encounter, which edges from documentation into decision support and carries a different risk profile from note generation. Held at B because no confidence threshold, acceptance rate or edit burden figure is published.

The pipeline is described at a high level, speech to text producing a transcript which machine learning and natural language processing convert into a note, which is more mechanical detail than several competitors give. Beyond that there is no accuracy figure, no evaluation methodology, no model card and no named models. The OEM structure adds a second layer of opacity a buyer should account for: the party accountable for model behaviour is AvodahMed, whose own disclosures are separate from Veradigm's, so diligence questions asked of Veradigm may not be answerable by Veradigm.

Named physician testimonials only, including a medical director quoted at launch and a family medicine physician reporting improved documentation quality after six months of use. No study, no controlled comparison, no accuracy benchmark and no third party performance rating located. Graded C on the standing precedent that satisfaction anecdotes do not substitute for evidence of benefit.

Contains the single most interesting privacy claim located in this category and is held at B only because it needs confirming. Veradigm describes the capture path as using speech to text to create real time encounter transcripts WITHOUT GENERATING AUDIO RECORDINGS. If that holds contractually it is engineered privacy rather than promised privacy, in the same class as Inspiren's camera free sensor design, because an audio artifact that never exists cannot be retained, breached, subpoenaed or used for training. The claim appears in a Veradigm explainer article rather than a product security page or trust centre, and no retention schedule or training use statement was located, so this is the first thing to get in writing. Confirmed, it would be an A.

Not assessed. Contracted within the Veradigm EHR relationship, but no product specific business associate agreement posture was located in this pass. The OEM structure makes this worth pressing: a buyer should establish whether the BAA chain reaches AvodahMed as a subcontractor and on what terms.

Not assessed. No named or dated attestation for this module, and no trust centre, was located in this pass.

Not a regulated medical device and no clearance is claimed or required for ambient documentation.

One honest scope statement, no governance disclosure. The honest part: Veradigm states that multilingual capture produces ENGLISH documentation output, which tells a buyer plainly that the note will not be in the language the visit was conducted in. Most vendors marketing multilingual capability blur exactly that distinction. What is absent is everything else: no fairness statement, no subgroup analysis, no accent or dialect performance disclosure, and no acknowledgement that a transcript produced from a non English conversation and rendered into English involves a translation step whose errors are invisible to a reviewer reading only the output.

Deep inside Veradigm and unavailable outside it, the same shape as the other EHR native scribes here. Notes land directly in the Veradigm EHR, capture runs through a dedicated mobile application, and enhancements reach customers through phased rollout without system upgrades or lengthy implementation cycles, which is a genuine advantage of native delivery. Worth noting that Veradigm also runs an app marketplace listing competing scribes, so native does not mean exclusive even inside its own base.

Not assessed. Cloud delivered with mobile capture, but no hosting region, residency or sub processor detail was located, and the OEM relationship makes the sub processor question materially more important here than for a first party product.

No published rate card and no standalone price. Sold within the Veradigm EHR relationship. One procurement fact belongs in the commercial assessment rather than buried: Veradigm's own investor releases carry the ticker OTCMKTS MDRX, meaning the parent trades over the counter rather than on a national exchange. That is a supplier continuity question of the kind this index has flagged before, and it applies to the party carrying the contract rather than to the quality of the product.

Ambulatory, bounded by the Veradigm installed base, and thinly documented. Note types named are SOAP, clinical and referral. No specialty count, no specialty tuning claim and no list of supported capture languages is published, so coverage cannot be compared with the enumerated ranges published by competitors in this category. Documentation output is English regardless of capture language.